Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.84 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.84 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.84 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.84 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.84 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.51 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965138 | 1.00 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL961705 | 1.00 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12918259 | 0.98 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL960267 | 0.94 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL964374 | 0.94 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL960268 | 0.94 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12918266 | 0.94 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Trifluoroacetic Acid SCHEMBL961400 | 0.94 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL961851 | 0.92 | PSEN1 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL963047 | 0.92 | PSEN1 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | claimed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | claimed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | claimed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | claimed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | claimed |
| US-20230029372-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-01-26 | — | — | US | disclosed |
| US-10925872-B2 | Methods of treating cochlear synaptopathy | Pipeline Therapeutics, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190307746-A1 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | CONTINEUM THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029372-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | PSEN1 15/4885PSEN2 26/4885APH1B 241/4885 |
| US-20190307746-A1 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | BACE1, SYPL1, SNAP23 | PSEN1 4/4885PSEN2 7/4885APH1B 50/4885 |
| US-10925872-B2 | Methods of treating cochlear synaptopathy | BACE1, SYPL1, SNAP23 | PSEN1 4/4885PSEN2 7/4885APH1B 50/4885 |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | PSEN1 6/4885PSEN2 7/4885APH1B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.